20 results on '"Tandstad, T."'
Search Results
2. PO-1468 Influence of PSMA-PET on treatment of prostate cancer patients with biochemical recurrence
3. 708MO Metachronous contralateral testicular cancer in the cisplatin era: A population-based cohort study
4. 785P Thromboembolic events (TE) during treatment with cisplatin-based chemotherapy (CBCT) in metastatic testicular germ-cell cancer (TC)
5. Location and histology of retroperitoneal metastases in post-chemotherapy retroperitoneal lymph node dissection for non-seminoma germ cell tumour
6. Redefining the IGCCCG classification in advanced non-seminoma
7. Current clinical management of relapsed testicular cancer, including the SWENOTECA experience
8. Increased risk of non-germ cell second cancer (SC) after cisplatin-based chemotherapy (CBCT) in 1-year testicular cancer (TC) survivors (TCS)
9. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
10. Ten thousand attentive hours, rapid learning, dissemination of knowledge and the future of experience-based care in germ-cell tumors
11. Reply to ‘The challenge to one course carboplatin in seminoma clinical stage 1’ by Dieckmann and Anheuser
12. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
13. Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors
14. 2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma
15. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer
16. Primum non nocere: do we harm stage I testicular cancer patients less by applying adjuvant chemotherapy than by failing to present this option?
17. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group
18. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
19. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study
20. 4512 POSTER Risk-adapted treatment in clinical stage 1 (CS1), non-seminomatous germ cell testicular cancer (NSGCT)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.